Review maps organoids and assembloids for glioblastoma research

Medical Oncology’s 2026 review, volume 43, issue 11, article 354, reports neither new experimental findings nor a survival benefit. Authors Büşra Yüksel, Ayşegül Doğan and Fikrettin Şahin instead assess why laboratory models struggle to reproduce glioblastoma and whether organoids and assembloids can narrow that gap. The DOI is 10.1007/s12032-026-03472-7.

Glioblastoma remains the most common malignant tumour of the adult central nervous system. The review says outcomes have barely shifted despite the standard combination of surgery, radiotherapy and chemotherapy, and it attributes part of the problem to models that cannot reproduce the disease’s lethal biology. The paper bears the title Modelling glioblastoma with organoids and assembloids: Opportunities and challenges.

What makes glioblastoma difficult to model?

• Intratumoral heterogeneity: Distinct cell populations with different molecular characteristics coexist within one tumour mass.
• Invasive growth: The tumour spreads into surrounding brain tissue.
• Microenvironment dependence: Non-tumour cells and surrounding structures influence tumour behaviour and treatment response.

The authors argue that flat two-dimensional cultures cannot reproduce these properties together, while simplified three-dimensional systems also miss much of that complexity. Their position does not dismiss every conventional model; the review weighs each approach’s strengths and limits.

What can organoids add to laboratory workflows?

Organoid technologies grow three-dimensional cultures from patient-derived cells. According to the review, these cultures preserve patient-specific molecular profiles and a degree of spatial organization that conventional cultures lack. A model can therefore retain the individual biological signature of its source tumour, which the authors treat as an essential requirement for personalised therapeutic strategies.

The review positions organoids as physiologically relevant systems that bring laboratory experimentation closer to the reality of the disease in patients. This is a platform claim, not a new clinical result: the article reports no patient-response test, no treatment comparison and no survival endpoint for organoid-guided care.

How do assembloids extend those systems?

The review treats assembloids as the more advanced platform because they integrate multiple cellular components into a single construct. That configuration allows researchers to investigate glioblastoma invasion into surrounding tissue, cellular plasticity driven by the microenvironment and the mechanisms underlying therapeutic resistance. Each target maps directly to a feature the review identifies as difficult to study in simpler models.

Resistance to standard care is a central reason mortality remains high, the authors argue. Models that recreate microenvironment-driven behaviour could therefore support translational research, but the review presents that benefit as potential rather than an achieved outcome.

What does the review actually establish?

As a review, the article synthesises the strengths and limitations of current two- and three-dimensional in-vitro models, highlights recent innovations and assesses how far the field has come. It reports no original experiments, sample sizes, assay protocols, prospective patient cohorts, cost estimates, head-to-head performance metrics or patient outcomes.

The supplied source identifies no funder for the review or the studies it discusses, leaving sponsorship and study-level methods unresolved within the item. No claim in the review establishes that a model predicts treatment response in patients or improves outcomes.

How should laboratories weigh the platforms?

• Match the platform to the biological question. Use organoids when the stated requirement is patient-specific molecular profiles and spatial organization; use assembloids when the question depends on invasion, microenvironment-driven plasticity or resistance mechanisms involving multiple cellular components.
• Retain a comparator. The critique of flat and simplified three-dimensional cultures does not amount to proof that either platform should replace them. Comparative validation remains outside the evidence presented here.
• Separate capability from performance. Preserved profiles and spatial organization describe what the platforms aim to retain. Predictive accuracy, reproducibility and translational usefulness require evidence not supplied by this review.
• Do not infer budget value. The paper gives no cost, cycle-time, batch-throughput or failure-rate data. It cannot by itself justify moving assay capacity or research funds toward either platform.

For R&D managers, the paper offers a capability map rather than a procurement case. A programme can use it to frame which biological question warrants greater model complexity, but it still needs primary validation, documented protocols and operating metrics before reallocating assay capacity or increasing budgets.

The review’s forward-looking proposition is that organoids and assembloids, once their remaining limitations are resolved, could strengthen the foundation for more effective and personalised glioblastoma therapies. The source presents that possibility, not a clinical result.